EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSHCOG00000010548
Gene Symbol: LOC109510493
3 Cross references
177 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSHCOG00000019374
Gene Symbol: LOC109528553
3 Cross references
196 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSHCOG00000020799
Gene Symbol: LOC109511122
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSHCOG00000008807
Gene Symbol: LOC109527809
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSHCOG00000018575
Gene Symbol: LOC109528057
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSHCOG00000018551
Gene Symbol: LOC109528058
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSHCOG00000005151
Gene Symbol: LOC109523795
3 Cross references
226 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-2-Like

Ensembl ID : ENSHCOG00000002098
Gene Symbol: LOC109507586
3 Cross references
209 Possible Orthologues:

Wee1-Like Protein Kinase 1-A

Ensembl ID : ENSHCOG00000003415
Gene Symbol: LOC109515783
2 Cross references
141 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSHCOG00000002935
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:

Ensembl ID : ENSHCOG00000008408
Gene Symbol: -
Cross references: -
204 Possible Orthologues:

Ensembl ID : ENSHCOG00000016216
Gene Symbol: -
Cross references: -
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).